QLT has signed a settlement deal with TAP to settle a patent infringement suit between the companies, and will pay TAP US $ 112.5 million. The lawsuit was brought by TAP and its co-plaintiffs --- Takeda, Wako and Abbott in 2003 against QLT and co-defendant Sanofi-Synthelabo claiming that ALT infringed TAP’s patent through sales of QLT’s Eligard-brand products in the US and Canada. Also under the deal’s terms, co-defendant Sanofi will pay TAP US $ 45 million. Further, according to the settlement deal, TAP and its co-plaintiffs have granted to QLT a non-exclusive, perpetual, royalty-free license under their past and future patents to make, use and sell Eligard products in the US and Canada.
No comments:
Post a Comment